英偉達(NVDA.US)再創盤中歷史新高 較4月低位累升逾80%
晶片製造商英偉達(NVDA.US)周五股價再升1.3%,日內曾高見至歷史新高158美元,有望連續第五天上升。
英偉達自4月初觸及52周低位以來,以盤中高位計,該股已累升逾80%,其最新市值升上3.8萬億美元,已超越微軟(MSFT.US)和蘋果(AAPL.US)重新成為美股中最有價值公司。
瑞銀重申對英偉達「買入」評級,指英偉達在該行第四次企業AI調查中,再次調查128間企業IT高層,了解他們在晶片、雲端基礎設施、模型、應用軟件、數據和安全層面的AI計劃,預期英偉達將成為人工智能的關鍵贏家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.